Edwards Lifesciences Corporation $EW Shares Sold by Midwest Professional Planners LTD.

Midwest Professional Planners LTD. lessened its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 21.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 28,991 shares of the medical research company’s stock after selling 7,779 shares during the period. Midwest Professional Planners LTD.’s holdings in Edwards Lifesciences were worth $2,471,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. JPL Wealth Management LLC acquired a new position in Edwards Lifesciences during the third quarter worth $25,000. Kohmann Bosshard Financial Services LLC acquired a new position in Edwards Lifesciences during the fourth quarter worth $28,000. Hantz Financial Services Inc. grew its holdings in Edwards Lifesciences by 76.6% during the third quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock worth $29,000 after acquiring an additional 164 shares during the period. Dorato Capital Management purchased a new stake in Edwards Lifesciences during the fourth quarter worth $29,000. Finally, Rakuten Securities Inc. boosted its position in Edwards Lifesciences by 413.7% during the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after purchasing an additional 302 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Activity

In other news, VP Donald E. Bobo, Jr. sold 9,968 shares of the company’s stock in a transaction on Friday, May 15th. The stock was sold at an average price of $82.07, for a total value of $818,073.76. Following the sale, the vice president directly owned 22,798 shares in the company, valued at $1,871,031.86. This represents a 30.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Daniel J. Lippis sold 620 shares of the company’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $81.14, for a total value of $50,306.80. Following the completion of the sale, the vice president owned 40,411 shares in the company, valued at $3,278,948.54. This represents a 1.51% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 106,684 shares of company stock worth $8,811,739 over the last three months. 0.31% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

EW has been the topic of a number of research analyst reports. Stifel Nicolaus set a $110.00 target price on Edwards Lifesciences and gave the stock a “buy” rating in a research report on Tuesday, January 20th. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Monday, April 20th. UBS Group reiterated a “neutral” rating and set a $94.00 target price on shares of Edwards Lifesciences in a research report on Wednesday, February 4th. The Goldman Sachs Group reiterated a “buy” rating and set a $95.00 target price (down from $108.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. Finally, Wolfe Research upgraded Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 target price on the stock in a research report on Wednesday, April 1st. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat, Edwards Lifesciences presently has an average rating of “Moderate Buy” and an average price target of $95.65.

Edwards Lifesciences Stock Down 0.3%

Shares of NYSE:EW opened at $82.13 on Wednesday. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $87.89. The stock’s fifty day simple moving average is $81.48 and its 200-day simple moving average is $82.87. The company has a market capitalization of $47.29 billion, a P/E ratio of 43.69, a P/E/G ratio of 2.07 and a beta of 0.87.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The business had revenue of $1.65 billion for the quarter, compared to the consensus estimate of $1.60 billion. During the same period in the prior year, the business earned $0.64 earnings per share. The business’s revenue was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, equities research analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.